Adamis Pharmaceuticals Corporation (Adamis), formerly Cellegy Pharmaceuticals, Inc.operates through its wholly owned subsidiaries Cellegy Holdings, Inc., Adamis Corporation and Biosyn, Inc. Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc. (Adamis Viral) and Adamis Laboratories, Inc. (Adamis Labs). Adamis Labs is a specialty pharmaceutical company. The Company focuses on developing and commercializing products in the anti-inflammatory, allergy and respiratory field that are commercialized by the Company. Additional product candidates in its allergy and respiratory product pipeline include a steroid HFA (hydrofluoroalkane) metered dose inhaler product, referred to as APC-1000, for asthma and chronic obstructive pulmonary disease (COPD); a generic High-functioning autism (HFA) bronchodilator, referred to as APC-2000; and an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis, referred to as APC-3000.